GLP-1 Medications and Muscle Loss: Why the Quality of Weight Loss Matters

Written By Sam Hetz

What the latest evidence means for longevity, strength, and long-term health

GLP-1 medications have changed the conversation around obesity, diabetes, metabolic health, and weight loss. Medications such as semaglutide and tirzepatide can produce substantial weight reduction and meaningful improvements in cardiometabolic risk factors. For many people, this represents a major advance in preventive medicine.

At LifespanMD, the clinical question is larger than weight loss alone.

The goal is not only to weigh less. The goal is to improve metabolic health while preserving muscle, strength, mobility, bone health, and long-term function. In longevity medicine, this is the difference between simply losing weight and improving healthspan.

A new 2026 study has brought this issue into sharper focus. Researchers are now testing whether medications that preserve lean mass can be paired with GLP-1 based therapies to improve the quality of weight loss. The early results are promising, although the practical message for patients remains clear: body composition, protein intake, resistance training, and clinical monitoring matter.

Why muscle matters during weight loss

When people lose weight, they usually lose a combination of fat mass and lean mass. Lean mass includes muscle, organs, connective tissue, water, and other non-fat tissue. While some lean mass reduction is expected during significant weight loss, excessive loss can be clinically important.

Muscle is not only important for appearance. It is metabolically active tissue that supports:

  • Strength

  • Mobility

  • Balance

  • Glucose control

  • Insulin sensitivity

  • Resting energy expenditure

  • Bone protection

  • Fall prevention

  • Independence with aging

In longevity medicine, muscle is a protective organ. Losing fat while preserving muscle improves the overall quality of weight loss. Losing weight while also losing too much strength can create new risks, especially in older adults, people with low baseline muscle mass, people with osteoporosis risk, and those already inactive before starting treatment.

What GLP-1 medications do well

GLP-1 receptor agonists and dual incretin medications can reduce appetite, improve satiety, lower caloric intake, and improve glycemic control. In people with obesity, diabetes, or elevated cardiometabolic risk, these medications can be powerful tools when prescribed appropriately.

Clinical trials have shown meaningful reductions in:

  • Body weight

  • Waist circumference

  • Blood glucose

  • Hemoglobin A1c

  • Blood pressure in some patients

  • Cardiovascular risk in selected high-risk populations

For the right patient, these effects can be highly relevant to long-term disease prevention.

The challenge is that weight loss alone does not tell the whole story. Two people can lose the same number of kilograms with very different results. One may lose mostly fat while preserving strength. Another may lose a larger proportion of lean mass and become weaker, less active, and metabolically more vulnerable over time.

This is why monitoring body composition matters.

The concern: how much lean mass is lost?

Across weight-loss interventions, a portion of weight loss comes from lean mass. With GLP-1 based therapies, studies have reported that lean mass can account for a meaningful share of total weight lost.

This does not mean these medications are inherently harmful to muscle. It means that a lower number on the scale is an incomplete outcome measure.

Some of the apparent lean mass change may reflect reductions in water, organ size, inflammation, liver fat, and other non-muscle tissue. However, muscle preservation remains clinically important because people using GLP-1 medications often eat less, may unintentionally underconsume protein, and may feel less motivated or energized to exercise during dose escalation.

The highest-risk scenario is predictable:

  • Rapid weight loss

  • Low protein intake

  • No resistance training

  • Low baseline muscle mass

  • Older age

  • Infrequent follow-up

  • Scale-only monitoring

  • No plan for long-term maintenance

That combination can produce weight loss while weakening the systems that protect long-term function.

The new 2026 study: can lean mass be protected pharmacologically?

In June 2026, a randomized, double-blind, placebo-controlled phase 2 study published in Nature Medicine tested apitegromab, an investigational monoclonal antibody that inhibits myostatin activation, in adults taking tirzepatide.

Myostatin is a protein involved in limiting muscle growth. Blocking myostatin is being studied as a strategy to preserve or increase lean mass.

In this study, 102 adults with overweight or obesity were randomized to receive tirzepatide plus apitegromab or tirzepatide plus placebo over 24 weeks.

The main finding was that total weight loss was similar between groups, but the group receiving apitegromab lost less lean mass.

At 24 weeks:

  • The apitegromab group lost about 1.6 kg of lean mass.

  • The placebo group lost about 3.5 kg of lean mass.

  • This represented about 1.9 kg less lean mass loss with apitegromab.

  • Lean mass loss represented 14.6% of total weight loss with apitegromab, compared with 30.2% with placebo.

  • Fat mass represented a larger proportion of total weight loss in the apitegromab group.

  • Adverse events were generally similar between groups in this short trial.

This is an important proof-of-concept study. It suggests that preserving lean mass during GLP-1 induced weight loss may be possible through targeted therapies.

However, this is not yet a routine clinical strategy. The trial was small, short, and mostly included women. Participants with diabetes and significant cardiometabolic disease were excluded. The study was not long enough to prove that preserving lean mass through this medication improves hard clinical outcomes such as falls, frailty, diabetes prevention, cardiovascular events, or long-term function.

The practical conclusion is not that every person on a GLP-1 medication needs another drug. The practical conclusion is that lean mass preservation is now becoming a central clinical outcome in weight-loss medicine.

What this means for patients today

For patients considering or using GLP-1 medications, the key issue is not whether the medication works. For many people, it does. The key issue is whether the program protects long-term health while weight is coming down.

A high-quality GLP-1 plan should include five elements.

1. Measure body composition, not only weight

A scale cannot distinguish fat loss from lean mass loss.

At minimum, patients should track:

  • Body weight

  • Waist circumference

  • Strength markers

  • Functional capacity

  • Energy levels

  • Physical activity

  • Protein intake

When available, body composition assessment can add important context. This may include bioelectrical impedance analysis, DEXA, 3D body scanning, or other validated tools, interpreted with an understanding of their limitations.

The goal is to identify the pattern of weight loss early. If weight is falling quickly while strength, energy, and lean mass are declining, the plan needs adjustment.

2. Prioritize protein intake

Protein is essential during weight loss because it supports muscle protein synthesis, satiety, immune function, and tissue repair.

Many adults underconsume protein during GLP-1 therapy because appetite is lower, portion sizes shrink, and nausea can reduce food intake. This can unintentionally worsen lean mass loss.

A practical target for many adults pursuing fat loss while preserving muscle is approximately 1.2 to 1.6 grams of protein per kilogram of body weight per day, individualized to kidney function, body composition, training status, age, and medical history.

For example:

  • A 70 kg adult may require approximately 84 to 112 grams per day.

  • An 85 kg adult may require approximately 102 to 136 grams per day.

  • Older adults, people training regularly, and those at risk of sarcopenia may require the higher end of the range.

Protein should usually be distributed across the day. A common structure is 25 to 40 grams per meal, adjusted to total daily needs.

3. Resistance training is non-negotiable

Cardio improves cardiovascular fitness, insulin sensitivity, mood, and endurance. Resistance training provides the mechanical signal required to preserve and build muscle.

A GLP-1 plan without resistance training is incomplete.

A practical minimum is:

  • 2 to 3 resistance training sessions per week

  • Full-body movement patterns

  • Progressive overload over time

  • Emphasis on large muscle groups

  • Safe technique and individualized programming

  • Tracking of strength progression

For beginners, this can start with machines, bands, body-weight exercises, or supervised coaching. For experienced individuals, a structured program with progressive loading is preferred.

The goal is not bodybuilding. The goal is to preserve the tissue that protects metabolism, mobility, and independence.

4. Monitor strength and function

Muscle mass matters, but function matters more.

Useful clinical markers include:

  • Grip strength

  • Sit-to-stand performance

  • Walking speed

  • Balance

  • Step count

  • Training load

  • Ability to climb stairs

  • Ability to carry groceries

  • Exercise recovery

  • VO2 max or cardiorespiratory fitness when available

If weight is decreasing while strength and function are stable or improving, the weight loss is more likely to be clinically favorable. If weight is decreasing while function is worsening, the plan needs reassessment.

5. Plan for maintenance from the beginning

Stopping GLP-1 therapy can lead to weight regain in many patients. This is not a failure of willpower. It reflects biology, appetite regulation, metabolic adaptation, and the chronic nature of obesity for many people.

This is why treatment should begin with a long-term plan.

A maintenance strategy should include:

  • Clear goals beyond body weight

  • Nutrition structure

  • Resistance training

  • Cardiovascular fitness

  • Sleep optimization

  • Alcohol review

  • Stress management

  • Follow-up cadence

  • Medication reassessment

  • Relapse prevention planning

At LifespanMD, this aligns with the broader goal of longevity medicine: build systems that can be sustained.

Who needs extra caution?

GLP-1 medications may be useful for many patients, but some groups require closer monitoring when weight loss is pursued.

These include:

  • Adults over 65

  • People with low baseline muscle mass

  • People with osteoporosis or fracture risk

  • People with prior falls

  • People with frailty or low mobility

  • People with chronic kidney disease

  • People with active gastrointestinal disease

  • People with eating disorder history

  • People with very low caloric intake

  • People losing weight rapidly

  • People using compounded or unregulated products

In these groups, the margin for error is smaller. Monitoring should be more structured.

What LifespanMD emphasizes

At LifespanMD, we view weight loss through a longevity lens. That means the desired outcome is not simply a lower body weight. The desired outcome is a stronger, more metabolically healthy, more resilient person.

A high-quality plan should answer the following questions:

  • Is fat mass decreasing?

  • Is lean mass being preserved as much as possible?

  • Is strength stable or improving?

  • Is cardiorespiratory fitness improving?

  • Is blood pressure improving?

  • Are glucose and insulin markers improving?

  • Are lipids and ApoB improving where relevant?

  • Is sleep improving?

  • Is the patient eating enough protein and micronutrients?

  • Is the plan sustainable?

This is the difference between medication-driven weight loss and medically supervised health optimization.

Bottom line

GLP-1 medications are one of the most important advances in metabolic medicine. They can be highly effective for the right patients. However, the quality of weight loss matters.

The emerging research on apitegromab and lean mass preservation highlights a major shift in the field: the future of weight-loss medicine will not be judged by kilograms lost alone. It will be judged by improvements in body composition, strength, metabolic health, and long-term function.

For now, the best evidence-based strategy remains clear:

  • Use GLP-1 medications only when clinically appropriate.

  • Track body composition and function, not only weight.

  • Prioritize adequate protein.

  • Build resistance training into the plan from the start.

  • Monitor strength, fitness, and metabolic markers over time.

  • Treat weight loss as part of a broader longevity strategy.

At LifespanMD, our goal is to help clients live better, longer. That means protecting the muscle, fitness, and function that make longer life worth living.

References

Pratley RE, Denham DS, Trivedi R, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine. Published June 8, 2026.

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.

Wilding JPH, Batterham RL, Davies M, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society. 2021.

Look M, Kolterman O, Jenkinson C, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 trial. Diabetes, Obesity and Metabolism. 2025.

Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021.

Jensen SBK, Janus C, Lundgren JR, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Network Open. 2024.

Deutz NEP, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clinical Nutrition. 2014.

Nowson C, O’Connell S. Protein requirements and recommendations for older people: a review. Nutrients. 2015.

Codella R, et al. GLP-1 agonists and exercise: the future of lifestyle prioritization. 2025.

Sam Hetz
Next

The Longevity Conversation Is Changing: From Biohacking to Measurable Healthspan